Clinical Trial Update: Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating siplizumab with dose-adjusted EPOCH-Rituximab in T- and NK-cell lymphomas has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gamma-damma Hepatosplenic T-cell Lymphoma
• Nk T-cell Lymphoma
• Subcutaneous Panniculitis-like T-cell Lymphoma
• T-cell Peripheral Lymphoma

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2020-08-18